APTO Aptose Biosciences Inc.

2.87
+0.1  (+4%)
Previous Close 2.77
Open 2.82
Price To Book 10.25
Market Cap 159,101,139
Shares 55,435,937
Volume 286,318
Short Ratio
Av. Daily Volume 419,748

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b clinical hold released June 29, 2018. First patient of re-initiation announced November 26, 2018. Primary completion 1H 2020.
APTO-253
Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Phase 1 safety/response data due late-2019.
CG-806
Chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL)

Latest News

  1. The Zacks Analyst Blog Highlights: Middlesex Water, Howard Hughes, Ubiquiti, Aptose and Aytu
  2. Bond Yields Plunge Globally on Slowdown Fears: 5 Safe Picks
  3. Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association
  4. Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
  5. Aptose Appoints Jotin Marango, M.D., Ph.D. as Chief Business Officer
  6. Aptose Announces Closing of Public Offering of Common Shares
  7. Aptose to Present at the Jefferies 2019 Healthcare Conference
  8. Aptose Announces Pricing of Public Offering of Common Shares
  9. Aptose Announces Proposed Public Offering of Common Shares
  10. Aptose Biosciences Establishes New At-The-Market Facility
  11. Aptose to Present New Preclinical Data for CG-806 at the 24th Congress of The European Hematology Association
  12. Aptose to Present at May Investor Conferences
  13. Aptose Announces Commencement of Previously Announced $20.0 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC
  14. Aptose Biosciences: 1Q Earnings Snapshot
  15. Aptose Reports Results for the First Quarter Ended March 31, 2019
  16. Aptose to Present at the Bloom Burton & Co. Healthcare Investor Conference 2019
  17. Aptose To Release First Quarter Ended March 31, 2019 Financial Results and Hold Conference Call on May 7, 2019
  18. Aptose to Present at the H.C. Wainwright Annual Global Life Sciences Conference
  19. Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806